PerkinElmer received FDA Emergency Use Authorization for respiratory SARS-CoV-2 panel
On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use…
Duke University-led study showed Vaxart’s oral COVID-19 vaccine candidate reduced transmission of SARS-CoV-2 infection
On Oct. 7, 2021, Vaxart announced that a Duke University-led study published in bioRxiv showed that Vaxart’s (investigational…
Labcorp received EUA for at home collection kit for combined COVID-19 and flu detection
On Oct. 1, 2021, LabCorp announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
Pfizer announced Study of mRNA-based next generation flu vaccine program
On Sept. 27, 2021, Pfizer announced that the first participants have been dosed in a Phase 1 clinical…
Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious Diseases
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
Novavax initiated phase 1/2 clinical trial of combination vaccine for COVID-19 and seasonal influenza
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
Newly licensed U.S. manufacturing facility increased availability of Fluzone high-dose quadrivalent (influenza vaccine)
On Jun. 17, 2021, the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research granted…
Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, the National Institutes of Health (NIH) announced the first-in-human, Phase 1 trial assessing the…
Novavax announced positive preclinical data for combination influenza and COVID-19 vaccine candidate
On May 10, 2021, Novavax announced data from a preclinical study of the company’s combination quadrivalent seasonal flu…
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
BD announced FDA Emergency Use Authorization for combination COVID-19, flu rapid antigen test
On Mar. 30, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) granted emergency use…
Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for…
Altasciences announced phase I research for COVID-19 pneumonia treatment
On Mar. 3, 2021, Altasciences announced support for ReAlta Life Sciences’ Phase I trial to evaluate RLS-0071 for…
First identification of human cases of avian influenza A(H5N8) infection
On Feb. 20, 2021, Russian authorities reported the detection of influenza A(H5N8) virus infection in seven poultry workers…
Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
NIH study of Intranasal influenza vaccine spurred strong immune response in Phase 1 study
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
CDC study showed 2019-20 flu vaccine effectively prevented hospitalizations and emergency visits in children
On Jan. 27, 2021, a U.S. Centers for Disease Control and Prevention (CDC) study found that the 2019-2020…
Roche’s Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 years
On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluza (baloxavir marboxil) for the…
Biotechnology | COVID-19 | HIV | Influenza | Vaccine
Moderna announced three new development programs in infectious disease vaccines
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls
On Jan. 7, 2021, Twist Bioscience announced it would supply the U.S. Centers for Disease Control and Prevention…
Quidel received Emergency Use Authorization for QuickVue SARS rapid antigen test for COVID-19 diagnosis
On Dec. 21, 2020, Quidel announced that it had received Emergency Use Authorization from the U.S. Food and…
Mount Sinai researchers advanced universal influenza virus vaccine
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
FDA authorized first COVID-19 and flu combination test for use with home-collected samples
On Dec. 4, 2020, the U.S. Food and Drug Administration (FDA) authorized the first diagnostic test for at home collection…
High-dose influenza vaccine showed no additional benefit for heart disease patients
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…
Roche announced FDA approval of Xofluza for prevention of influenza following contact with infected person
On Nov. 24, 2020, Roche announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental…
FDA expanded approval of influenza treatment to post-exposure prevention
On Nov. 23, 2020, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Genentech’s Xofluza…
Avian influenza virus spread rapidly in Europe
On Nov. 20, 2020, the ‘European Food Safety Authority reported that within the past month more than 300…
XBiotech data showed effective anti-virus activity for antibodies in candidate influenza-COVID-19 therapeutic
On Nov. 19, 2020, XBiotech announced data for its breakthrough candidate therapy for treating infections of influenza and…